<DOC>
	<DOCNO>NCT02059174</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics , pharmacodynamics MK-1293 compare basal insulin ( EU-Lantusâ„¢ ) participant Type 1 Diabetes . The primary hypothesis duration action , pharmacodynamic profile , pharmacokinetic profile MK-1293 comparator basal insulin similar .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics MK-1293 Compared With Basal Insulin Participants With Type 1 Diabetes ( MK-1293-005 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Has type 1 diabetes mellitus diagnose least 12 month screen Subject investigator discretion , stable dose insulin least 2 week screen Has total daily insulin dose &lt; =1.2 units/kg Has screening hemoglobin A1c &lt; 9.5 % Has body mass index &gt; 18.0 &lt; =30.0 kg/m^2 Has weight &gt; =50 kg Female participant reproductive potential serum betahuman chorionic gonadotropin level consistent nongravid state agrees use ( and/or partner use ) 2 acceptable method birth control 2 week last dose study drug Postmenopausal female participant without menses &gt; =1 year Surgically sterile female participant status post hysterectomy , oophorectomy , tubal ligation Has use nicotine nicotinecontaining product least 3 month study start smoke less 10 cigarette per day willing abstain trial Has history clinically significant gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary , major neurological abnormality disease Has history clinically significant endocrine abnormality diseases except type 1 diabetes mellitus Has severe hypoglycemic episode associated hypoglycemic seizure , coma , unconsciousness within past 3 month Has history diabetic ketoacidosis within past 6 month Has history significant multiple severe allergy , anaphylactic reaction , significant intolerability drug food Has history hypersensitivity pharmacologic insulin Is positive hepatitis B surface antigen , hepatitis C , Human Immunodeficiency Virus Has major surgery donate lose 1 unit blood within 4 week screen Unable refrain use medication herbal remedy 2 week prior first dose study drug posttrial visit . Some medication permit may discuss investigator Vaccination within 12 week start study participation Consumes &gt; 3 glass alcoholic beverage per day . Participants consume 4 glass alcoholic beverage may enrol discretion investigator . Consumes &gt; 6 serving caffeinated beverage per day Is regular user illicit drug history drug abuse ( include alcohol ) within approximately 1 year Is carbohydraterestricted diet ( &lt; 100 gram carbohydrate per day ) ; participant carbohydraterestricted diet may include agree diet consist &gt; =100 gram carbohydrate daily throughout study Has personal family history hypercoagulability thromboembolic disease Has use systemic glucocorticoid within 3 month screen anticipates treatment systemic glucocorticoid study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>